Patents by Inventor Yann Herault

Yann Herault has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220331333
    Abstract: The present invention relates to the prevention and/or treatment of a neurodevelopmental disorder or a neuropsychiatric disorder comprising administering a therapeutically effective amount of fasudil or a derivative thereof or a pharmaceutical composition comprising fasudil or a derivative thereof, in a subject in need thereof.
    Type: Application
    Filed: April 13, 2022
    Publication date: October 20, 2022
    Inventors: Yann HERAULT, Sandra MARTIN LORENZO
  • Patent number: 9078874
    Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: July 14, 2015
    Assignee: Centre National De La Recherche Scientifique—CNRS
    Inventors: Marie-Caude Potier, Robert Dodd, Benoît Delatour, Jérôme Braudeau, Yann Herault
  • Publication number: 20140328864
    Abstract: The present invention relates to agent selected from the group consisting of an anti-S100B antibody, an anti-S100B aptamer or an inhibitor of S100B gene expression for use in a method for reducing airway hyperresponse in a subject in need thereof. The present invention also relates to a method for determining whether a subject is at risk of having or developing an airway hyperresonse comprising determining the level of S100B protein in a biological sample obtained from said subject.
    Type: Application
    Filed: November 22, 2012
    Publication date: November 6, 2014
    Applicants: INSERM (INSTITUT NATIONAL DE LA SENTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE STRASBOURG, CNRS (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE)
    Inventors: Yann Herault, Emilie Dalloneau
  • Publication number: 20120283248
    Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.
    Type: Application
    Filed: August 24, 2010
    Publication date: November 8, 2012
    Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS
    Inventors: Marie-Claude Potier, Robert Dodd, Benoît Delatour, Jérôme Braudeau, Yann Herault